{"id":5255,"date":"2026-03-18T09:30:24","date_gmt":"2026-03-18T04:00:24","guid":{"rendered":"https:\/\/economictimes.lk\/?p=5255"},"modified":"2026-03-18T09:30:26","modified_gmt":"2026-03-18T04:00:26","slug":"asiri-laboratories-introduces-biofire-filmarray-sri-lankas-first-rapid-infectious-disease-diagnostic-system","status":"publish","type":"post","link":"https:\/\/economictimes.lk\/index.php\/2026\/03\/18\/asiri-laboratories-introduces-biofire-filmarray-sri-lankas-first-rapid-infectious-disease-diagnostic-system\/","title":{"rendered":"Asiri Laboratories Introduces BioFire\u00ae FilmArray\u00ae \u2014 Sri Lanka\u2019s First Rapid Infectious Disease Diagnostic System"},"content":{"rendered":"\n

Revolutionary syndromic molecular testing platform delivers faster, more accurate results to<\/em><\/strong>\u00a0enhance patient outcomes and clinical decision-making<\/em><\/strong><\/p>\n\n\n\n

In a landmark step toward advancing infectious disease diagnostics, Asiri Laboratories<\/strong> has introduced the BioFire\u00ae FilmArray\u00ae System<\/strong> \u2014 a cutting-edge multiplex PCR platform that transforms pathogen detection with unmatched speed, accuracy, and confidence.<\/p>\n\n\n\n

This breakthrough marks a significant leap in Sri Lanka\u2019s diagnostic capability, empowering clinicians with rapid syndromic testing that enables simultaneous detection of 20 \u2013 30+ pathogens within 45\u201360 minutes<\/strong>, compared to days with conventional methods.<\/p>\n\n\n\n

In modern clinical practice, timely and precise diagnosis is critical for managing infectious diseases and controlling outbreaks. The BioFire\u00ae FilmArray\u00ae<\/strong> system directly addresses these challenges through syndromic molecular testing<\/strong>, identifying causative pathogens and antimicrobial resistance markers in a single, fully automated process.<\/p>\n\n\n\n

The current diagnostic panels include pneumonia, meningitis\/encephalitis and blood culture identification.<\/p>\n\n\n\n

With minimal hands-on time and seamless automation, the platform enables clinicians to rapidly initiate targeted therapies, optimize patient management, and reduce hospital stays \u2014 ultimately improving outcomes and efficiency across the healthcare continuum.<\/p>\n\n\n\n

Powered by nested multiplex PCR technology<\/strong>, the BioFire\u00ae FilmArray\u00ae provides superior sensitivity and specificity, even detecting polymicrobial infections often missed by conventional culture methods.<\/p>\n\n\n\n

Key advantages include results in approximately 1 hour from sample to answer, simultaneous detection of bacteria, viruses, yeasts, and resistance genes, a closed contamination-free testing process, approximately 2 minutes of hands-on time, value in critical and emergency care environments, and support for better antimicrobial stewardship through informed therapy decisions.<\/p>\n\n\n\n

Integrated into Asiri Laboratories\u2019 digital and automated workflow, this innovation reinforces its ongoing commitment to world-class diagnostics aligned with global standards<\/strong>.<\/p>\n\n\n\n

Mr. Neil Priyath John, <\/strong>Director \u2013 Laboratories at Asiri Health,<\/strong> \u201cThe BioFire\u00ae FilmArray\u00ae revolutionizes our infectious disease diagnostic capabilities and It enables faster and more precise results especially within critical and emergency care settings giving clinicians the insights they need when<\/p>\n\n\n\n

every minute counts.\u201d<\/p>\n\n\n\n

He further added: \u201cAs the pioneer in Sri Lanka\u2019s private diagnostics sector for over 40 years, Asiri Laboratories remains committed to adopting the latest global advancements. The introduction of the BioFire\u00ae FilmArray\u00ae sets a new national benchmark in rapid molecular testing.\u201d<\/p>\n\n\n\n

Dr. Sujatha Pathirage<\/strong>, Consultant Microbiologist, The BioFire\u00ae FilmArray\u00ae<\/strong>, the first of its kind in Sri Lanka, \u201cit is an automated PCR-based diagnostic system capable of detecting multiple targets simultaneously. These targets include bacterial, viral, and fungal pathogens, as well as antimicrobial resistance (AMR) genes. This enables comprehensive testing for all probable pathogens associated with specific clinical syndromes for example, respiratory infections, bloodstream infections, meningitis\/encephalitis, and gastroenteritis.\u201d<\/p>\n\n\n\n

Its rapid, simple, and comprehensive syndromic testing approach provides laboratory results within a clinically meaningful timeframe, allowing clinicians to make precise and timely decisions.<\/p>\n\n\n\n

Furthermore, the ability to detect multiple antimicrobial resistance genes supports the early selection of the most appropriate antibiotic therapy, ensuring optimal patient care and reducing the duration of<\/p>\n\n\n\n

hospital stay.<\/p>\n\n\n\n

Ms. Mihiri Cabandugama, <\/strong>Director \u2013 Strategic Planning & Business Development at Asiri Health, Emphasized that the adoption of BioFire\u00ae aligns with Asiri\u2019s continued long-term strategy of integrating world-class technology to elevate diagnostic excellence. She noted that this advancement further solidifies Asiri Health\u2019s position and commitment as Sri Lanka\u2019s leader in innovative, patient centered healthcare solutions.<\/p>\n\n\n\n

By enabling rapid detection of high-risk pathogens \u2014 including those causing meningitis and severe respiratory infections \u2014 the BioFire\u00ae FilmArray\u00ae enhances patient safety, infection control, and outbreak preparedness<\/strong>.<\/p>\n\n\n\n

Its rollout across the Asiri Laboratories network ensures nationwide access to world-class rapid molecular diagnostics<\/strong>, empowering clinicians to make informed treatment decisions that improve patient outcomes and curb antimicrobial resistance.<\/p>\n\n\n\n

\u201cWe at Analytical Instruments Pvt. Ltd.<\/strong> are proud to partner with Asiri Laboratories in bringing the globally acclaimed BioFire\u00ae FilmArray\u00ae platform to Sri Lanka,\u201d said Mr. S. Balamurugan<\/strong>, National Sales Manager. \u201cThis collaboration underscores our shared mission to deliver cutting-edge technologies that elevate the standard of diagnostic care across the nation.\u201d<\/p>\n\n\n\n

END<\/strong><\/strong><\/p>\n\n\n\n

About Asiri Laboratories<\/strong><\/p>\n\n\n\n

Asiri Laboratories<\/strong>, part of Asiri Health<\/strong> under the Softlogic Holdings Group<\/strong>, is Sri Lanka\u2019s leading private diagnostic service provider with over four decades of trusted expertise. Renowned for technological leadership and quality excellence, Asiri Laboratories operates an island-wide network of 116 laboratories across Sri Lanka<\/strong>, ensuring enhanced accessibility and greater convenience for patients.<\/p>\n\n\n\n

The network offers advanced pathology, microbiology, and molecular diagnostic services that meet international standards of accuracy, reliability, and efficiency upholding Asiri Laboratories\u2019 position as the country\u2019s most trusted partner in diagnostic care.<\/p>\n\n\n\n

About Analytical Instruments Pvt. Ltd.<\/strong><\/p>\n\n\n\n

Analytical Instruments Pvt. Ltd.<\/strong> is a leading provider of cutting-edge scientific and diagnostic solutions in Sri Lanka. Representing globally reputed brands, the company is committed to enabling advancements in healthcare, research, and industrial testing through world-class instrumentation, comprehensive training, and technical support backed by over 37 years of experience.<\/p>\n","protected":false},"excerpt":{"rendered":"

Revolutionary syndromic molecular testing platform delivers faster, more accurate results to\u00a0enhance patient outcomes and clinical…<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[5],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/posts\/5255"}],"collection":[{"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/comments?post=5255"}],"version-history":[{"count":1,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/posts\/5255\/revisions"}],"predecessor-version":[{"id":5256,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/posts\/5255\/revisions\/5256"}],"wp:attachment":[{"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/media?parent=5255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/categories?post=5255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economictimes.lk\/index.php\/wp-json\/wp\/v2\/tags?post=5255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}